Anti-IL-17Ra / CD217 Reference Antibody (brodalumab) is a key tool in immunology research and development, particularly for studying the IL-17 cytokine signaling pathway involved in various chronic inflammatory diseases, such as plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and Crohn's disease.

In therapeutic applications, brodalumab is developed as a monoclonal antibody inhibitor for treating moderate to severe plaque psoriasis in patients unresponsive to other systemic therapies. It binds to the IL-17RA receptor, blocking IL-17 cytokine activity to significantly reduce skin inflammation, lesion formation, and tissue damage. It is also under investigation for psoriatic arthritis and other IL-17-mediated conditions and is administered via subcutaneous injection.

Additionally, this reference antibody serves as a standard for developing and validating other commercial antibodies, assessing specificity, potency, and inhibitory efficacy against the same target in laboratory settings. It is used in quality control for biopharmaceutical production.